Márcia Vieira-Coimbra

Dr. Márcia Vieira-Coimbra


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GOGonçalo Outeiro-Pinho
Gonçalo Outeiro-Pinho
DBDaniela Barros-Silva
Daniela Barros-Silva
EAElena Aznar
Elena Aznar
ASAna-Isabel Sousa
Ana-Isabel Sousa
MVMárcia Vieira-Coimbra
Márcia Vieira-Coimbra
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Background: The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods: Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively assessed by PCR in a tissue set (Cohort #1) and urine sets (Cohorts #2 and 3) from IPOPorto and Homburg University Hospital. Non-parametric tests were used for comparing continuous variables. MiR-30a-5p promoter methylation (miR-30a-5pme) performance as diagnostic (receiver operator characteristics [ROC] - validity estimates) and prognostic [metastasis-free (MFS) and disease-specific survival (DSS)] biomarker was further validated in urine samples from ccRCC patients by Kaplan Meier curves (with log rank) and both univariable and multivariable analysis. Results: Two significant hypermethylated CpG loci in TCGA ccRCC samples, correlating with miR-30a-5p transcriptional downregulation, were disclosed. MiR-30a-5pme in ccRCC tissues was confirmed in an independent patient’s cohort of IPOPorto and associated with shorter time to relapse. In urine samples, miR-30a-5pme levels identified cancer both in testing and validation cohorts, with 83% sensitivity/53% specificity and 63% sensitivity/67% specificity, respectively. Moreover, higher miR-30a-5pme levels independently predicted metastatic dissemination and survival. Conclusion: To the best of our knowledge, this is the first study validating the diagnostic and prognostic potential of miR-30a-5pme for ccRCC in urine samples, providing new insights for its clinical usefulness as non-invasive cancer biomarker.

20 October 2021
Verified
Conference Paper
Open access
MVMárcia Vieira-Coimbra
Márcia Vieira-Coimbra
Problem Stated: Cerebral Venous Thrombosis (CVT) is a rare cause of cerebral ischemia, corresponding to approximately 0.5% of stroke cases. CVT usually appears in the venous sinuses, which includes the lateral venous sinus. Among the risk factors associated with CVT, the puerperium is a phase in which thrombotic risk is particularly increased. The present work aims to describe the